Oruka Therapeutics logo

Scientist/Senior Scientist, Upstream, Process Development & Manufacturing (Biologics)

Oruka Therapeutics

Menlo Park, CA; Waltham, MAHybridPosted 1 day ago$161,000 - $187,000/year
Full TimeSenior LevelManufacturing & CMCBiotechnology
Original posting ↗

Summary

We are seeking an experienced and motivated Scientist/Senior Scientist to support cell culture and cell line development activities. This role will be instrumental in contributing to early-phase process development and delivery of clinical trial material at CDMOs. The ideal candidate will collaborate cross-functionally within the CMC team including downstream, analytical, and drug product and other stakeholders such as QA, regulatory, and program management. The successful candidate will help support CMC strategy in a fast-paced, innovative environment.

Job description

Position Overview

We are seeking an experienced and motivated Scientist/Senior Scientist to support cell culture and cell line development activities. This role will be instrumental in contributing to early-phase process development and delivery of clinical trial material at CDMOs. The ideal candidate will collaborate cross-functionally within the CMC team including downstream, analytical, and drug product and other stakeholders such as QA, regulatory, and program management. The successful candidate will help support CMC strategy in a fast-paced, innovative environment.

Key Responsibilities

  • Drive cell line development and upstream cell culture process development, oversee manufacturing execution at external CDMOs.
  • Contribute technical expertise to early-phase upstream process development, scale-up, and tech transfer to secure reliable drug substance supply.
  • Serve as person-in-plant (PIP) during critical manufacturing campaigns, troubleshooting and resolving issues in real time.
  • Proactively identify technical and development risks and implement phase-appropriate mitigation strategies.
  • Manage upstream timelines and deliverables to ensure on-time material delivery and seamless handoffs to downstream, analytical, and drug product teams.
  • Apply phase-appropriate QbD principles and analyze process data to guide development decisions.
  • Travel up to 25% to support on-site CDMO activities.

Qualifications

  • PhD with 3+ years or Master's with 5+ years of industry experience in Biological Sciences focused on upstream process development and/or cell line development.
  • Strong hands-on expertise in CHO cell line and/or cell culture process development, scale-up, and bioreactor operations; experience with monoclonal antibody (mAb) production preferred.
  • Solid understanding of upstream process parameters and product quality attributes, with experience troubleshooting during clinical manufacturing.
  • Experience supporting or leading upstream tech transfer to CDMOs.
  • Familiarity with phase-appropriate cGMP requirements and regulatory expectations for biologics development.
  • Demonstrated ability to analyze and interpret process and manufacturing data.

Requirements

  • PhD with 3+ years or Master's with 5+ years of industry experience in Biological Sciences focused on upstream process development and/or cell line development
  • Strong hands-on expertise in CHO cell line and/or cell culture process development, scale-up, and bioreactor operations
  • Experience with monoclonal antibody (mAb) production preferred
  • Solid understanding of upstream process parameters and product quality attributes
  • Experience troubleshooting during clinical manufacturing
  • Experience supporting or leading upstream tech transfer to CDMOs
  • Familiarity with phase-appropriate cGMP requirements and regulatory expectations for biologics development
  • Demonstrated ability to analyze and interpret process and manufacturing data

Benefits

  • Competitive salary
  • Equity
  • Performance-related bonus
  • Professional growth and development

Company overview

Oruka Therapeutics is a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, particularly plaque psoriasis. The company's mission is to offer patients suffering from chronic skin conditions the greatest possible freedom from disease by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies targeting core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. Their lead candidates include ORKA-001, a long-acting anti-IL-23p19 antibody with approximately 100-day half-life, and ORKA-002, a long-acting anti-IL-17A/F antibody. The company is publicly traded on NASDAQ under the ticker ORKA and has recently secured $180 million in financing to advance its clinical programs through multiple Phase 2 readouts expected in 2027.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.